Table 2.

Correlation Between Average Methylation of 10 Genes (by z score) and Clinical Features

Characteristic	Training Cohort			First Validation Cohort			Second Validation
	Mean z Score	SD	P	Mean z Score	SD	P	Mean z Score	SD	P
Age, years
< 45	−0.16	0.12	.11	−0.38	0	.09	0.49	0.63	.11
45-65	0.08	0.83		0.12	0.37		0.32	0.61
> 65	−0.04	0.49		0.23	0.39		0.14	0.63
Sex
Male	−0.07	0.48	.17	0.18	0.41	.52	0.24	0.64	.87
Female	0.16	0.84		0.13	0.30		0.22	0.60
Hemoglobin level, g/dL
< 10	0.05	0.65	.41	0.20	0.37	.39	0.25	0.67	.73
≥ 10	−0.07	0.56		0.11	0.42		0.21	0.58
Absolute neutrophil count, × 109/L
< 1.8	−0.05	0.48	.19	0.21	0.36	.27	0.33	0.66	.03
≥ 1.8	0.21	0.88		0.10	0.45		0.12	0.57
Platelet count, × 109/L
< 100	0.03	0.64	.69	0.15	0.41	.66	0.30	0.63	.10
≥ 100	−0.03	0.61		0.25	0.33		0.13	0.61
Marrow blast percentage
< 5	−0.08	0.38	.80	0.13	0.42	.66	0.10	0.59	.01
5-10	0.00	0.56		0.13	0.40		0.29	0.58
11-20	0.11	0.92		0.24	0.38		0.31	0.66
21-30	0.08	0.54		0.18	0.11		0.60	0.67
IPSS risk category
Low	NA		.18	0.83	0.89	.30	−0.02	0.53	.01
Intermediate-1	−0.29	0.41		0.03	0.43		0.19	0.61
Intermediate-2	−0.02	0.77		0.24	0.32		0.29	0.59
High	0.02	0.46		0.34	0.50		0.53	0.72
FAB type
Refractory anemia	−0.12	0.41	.44	0.29	0.71	.67	0.09	0.51	.002
Refractory anemia with ringed sideroblasts	−0.25	0.43		−0.07	0.27		−0.10	0.54
Refractory anemia with excess blasts	0.07	0.70		0.17	0.31		0.43	0.68
Chronic myelomonocytic leukemia	−0.08	0.44		0.17	0.52		0.18	0.52
Karyotype
Good	−0.08	0.53	.07	0.14	0.42	.14	0.17	0.62	.42
Intermediate	0.18	0.50		0.14	0.42		0.32	0.72
Poor	−0.07	0.37		0.28	0.24		0.28	0.55
MDS type
De novo	−0.02	0.65	.12	0.16	0.44	.80	0.25	0.63	.51
Secondary	0.11	0.38		0.19	0.24		0.18	0.62

Abbreviations: SD, standard deviation; ANC, absolute neutrophil count; IPSS, International Prognostic Scoring System; FAB, French-American-British; MDS, myelodysplastic syndrome.